[Myelodysplastic syndrome].
Myelodysplastic syndrome (MDS) is a heterogenous syndrome which has features of refractory anemia and preleukemic state due to the ineffective hematopoiesis of bone marrow cells. MDS is classified by the FAB classification and/or WHO classification, and has an International Prognostic Scoring System (IPSS) for evaluation of the prognosis. Available therapies consist of a variety of modalities from supportive therapy to hematopoietic stem cell transplantation, and are selected according to the condition of each patient.
Urabe
Akio
A
Division of Hematology, NTT Kanto Medical Center, Tokyo, Japan.
D000753:Anemia, Refractory / Q000175:diagnosis; D000754:Anemia, Refractory, with Excess of Blasts / Q000175:diagnosis; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage; D008775:Methylprednisolone / Q000008:administration & dosage; D009190:Myelodysplastic Syndromes / Q000145:classification / Q000175:diagnosis / Q000628:therapy; D011379:Prognosis; D014944:World Health Organization
D000961:Antilymphocyte Serum; D007166:Immunosuppressive Agents; D008775:Methylprednisolone